VERAXA Biotech (NASDAQ: VRXA) announced the successful closing of its previously announced business combination with Voyager Acquisition Corp., resulting in the formation of VERAXA Biotech AG, which began trading on the Nasdaq Capital Market on June 11, 2026, under the ticker symbol VRXA, with warrants trading under VRXAW. The company is developing a pipeline of bispecific T-cell engagers and antibody-drug conjugates based on its proprietary BiTAC platform, which is designed to selectively target cancer cells while sparing healthy tissue.
Proceeds from recently completed financings, including a $27.5 million senior secured note and a securities purchase agreement of up to $50 million, are expected to support advancement of its BiTAC-TCE and BiTAC-ADC programs toward clinical development. The company recently presented preclinical data at the AACR Annual Meeting 2026 demonstrating favorable efficacy and safety characteristics for its lead BiTAC-TCE candidate. According to the full press release, these funds will be used to push the pipeline into clinical trials.
The BiTAC platform, built on scientific breakthroughs made at the European Molecular Biology Laboratory, is designed to overcome limitations of traditional bispecific antibodies by optimizing T-cell engagement and payload delivery. VERAXA’s approach aims to improve therapeutic index, potentially offering better outcomes for patients with solid tumors and hematologic malignancies.
The business combination with Voyager Acquisition Corp., a special purpose acquisition company focused on healthcare, provides VERAXA with access to capital markets and a public listing. The combined entity is expected to accelerate the development of VERAXA’s pipeline, which includes multiple candidates in preclinical stages. Voyager’s management team brings expertise in investing, operations, and medical innovation, which could support VERAXA’s scaling efforts.
For investors and the biotech industry, VERAXA’s debut on Nasdaq signals continued interest in novel immunotherapies, particularly bispecific antibodies and ADCs, which represent a growing segment of the oncology market. The company’s focus on sparing healthy tissue could address a key challenge in cancer treatment: reducing side effects while maintaining efficacy. However, as with all early-stage biotech companies, the path to commercialization involves significant risks, including clinical trial outcomes, regulatory approvals, and market competition.
Forward-looking statements in the announcement caution that actual results may differ materially due to risks outlined in SEC filings, including those under "Risk Factors" in the company’s most recent Annual Report on Form 10-K. The company undertakes no duty to update these statements unless required by law. VERAXA’s progress will be closely watched by analysts and investors as it moves toward clinical development.
